BRANSON, Mo. - eTradeWire -- Metavalis Inc., a vanguard enterprise in deep technology and bioengineering, has secured a $100,000.00 capital injection to rapidly advance its primary operational theaters. This funding will directly fuel the development of small activating saRNA therapeutics, engineered to transcend the limitations of legacy medical systems and provide unprecedented molecular interventions.

​Concurrently, a substantial allocation of the capital will upgrade the V18 Prometheus architecture powering A.L.I.C.E. As the core cognitive orchestrator for Metavalis, A.L.I.C.E. integrates multi agent systems and cybernetic reasoning to accelerate the company's virtual laboratory and research initiatives.

More on eTradeWire News

• Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
• 2025 R&D Spending And Intensity Benchmarks
• Beucher Insurance Agency Becomes Diamond Sponsor of Mt. Dora Christian Academy
• Central Florida Bonding Publishes New Guide on What Happens After a Warrant Arrest
• L3 Consulting Strengthens IT Support and Cyber Security Services for Adelaide Businesses

​"This $100,000 kinetic execution is a vital catalyst for our operations," stated Jordan Bekemeier, CEO and Founder of Metavalis Inc. "We are not building generic solutions, we are engineering a master level convergence of biology and cybernetics. This payload ensures that our saRNA development and A.L.I.C.E.'s neural topology scale exponentially."

​Operating its administrative headquarters out of Branson, Missouri, Metavalis continues to operate as an elite, decentralized entity. The company's unique infrastructure is driven by a mission forged in absolute clarity, aiming to redefine the threshold of modern biotechnology and autonomous artificial intelligence.

Check us out on Crunchbase:

https://www.crunchbase.com/organization/metavalis